Clinical Trial: Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: HLH-2004 Treatment Protocol

Brief Summary: Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.

Detailed Summary: The most dangerous period after HLH diagnosis is the first 2 months. In HLH-2004 we provide additional therapy during this period as compared to in HLH-94.
Sponsor: Karolinska University Hospital

Current Primary Outcome: Survival [ Time Frame: 1-year after diagnosis ]

Original Primary Outcome: Survival

Current Secondary Outcome: Late effects [ Time Frame: 5-years after diagnosis ]

Original Secondary Outcome: Late effects

Information By: Karolinska University Hospital

Dates:
Date Received: January 23, 2007
Date Started: January 2004
Date Completion: December 2017
Last Updated: March 12, 2017
Last Verified: March 2017